Mizuho lifts target for Haemonetics stock to USD 140.00 with 15.57 percent upside opportunity

Published on 10/15/2026 at 21:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Haemonetics reports second-quarter results on November 5, 2026. Haemonetics stock costs EUR 107.50 on October 15, 2026 at 9:31 p.m. CEST.

Analyst valuation and upcoming results

Mizuho analyst Anthony Petrone set a USD 140.00 target on October 9, 2026, up from USD 95.00.
Haemonetics is scheduled to publish second-quarter fiscal year 2027 results on November 5, 2026.
Haemonetics stock costs EUR 107.50 at Lang & Schwarz on October 15, 2026 at 9:31 p.m. CEST.
Haemonetics had a USD 5.5 billion market capitalization on October 15, 2026.

HAE, US4050241003, Illustration mit AI erstellt.

Haemonetics (US4050241003) has a fresh USD 140.00 analyst target from Mizuho, which is 15.57 percent above the USD 121.14 home-market price. The target was raised from USD 95.00 on October 9, 2026, while the euro quotation stood at EUR 107.50 at Lang & Schwarz on October 15, 2026 at 9:31 p.m. CEST.

Results date sets the next marker

Haemonetics is scheduled to publish second-quarter fiscal year 2027 results on November 5, 2026, at 6:00 a.m. ET. The company said in its September 30, 2026 release that an investor and analyst conference call would follow at 8:00 a.m. ET. The date gives the market a defined point for testing the assumptions behind the higher analyst targets, according to the Haemonetics release.

Stock stays near its yearly high

On the New York Stock Exchange, Haemonetics was last at USD 121.14 on October 15, 2026 at 3:36 p.m. ET. Its session range was USD 118.65 to USD 122.46, and the 52-week range was USD 48.62 to USD 123.77 on the same date. The home-market price therefore sat 2.13 percent below its 52-week high, leaving the upper end of the range as the immediate chart marker.

Haemonetics reported first-quarter fiscal year 2027 revenue of USD 339.38 million, up 5.60 percent from a year earlier, while adjusted earnings per diluted share reached USD 1.14. The company also raised fiscal year 2027 reported revenue-growth guidance to 5.00 percent to 8.00 percent, according to Benzinga. That operating backdrop is the numerical test for the November report.

Valuation leaves a demanding hurdle

Haemonetics had a USD 5.5 billion market capitalization and a trailing P/E ratio of 59.34 on October 15, 2026. The Mizuho target implies a 15.57 percent premium to the USD 121.14 New York Stock Exchange price. Markets Insider reported that Mizuho retained its Outperform rating when lifting the target.

Comparison with peers

Haemonetics: P/E 59.34, market capitalization USD 5.5 billion.
Becton, Dickinson and Company: plus 2.69 percent, P/E 58.48, market capitalization USD 52.8 billion.
The Cooper Companies: plus 4.51 percent, P/E 19.57, market capitalization USD 10.9 billion.

Euro quote after the Xetra close

Haemonetics stood at EUR 107.50 at Lang & Schwarz on October 15, 2026 at 9:31 p.m. CEST. The quote gives German investors a euro-denominated view while the New York listing remained the primary market reference earlier in the day. The further course of trading is shown by the continuously updated real-time quote of Haemonetics stock.